133 related articles for article (PubMed ID: 38838294)
1. Expanding Access to Medications for Opioid Use Disorder: Federal Policy Is Only a Part of the Solution.
Heidari O; Banta-Green CJ
Am J Public Health; 2024 Jul; 114(7):693-695. PubMed ID: 38838294
[No Abstract] [Full Text] [Related]
2. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
[TBL] [Abstract][Full Text] [Related]
3. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
Ferrara MM
Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
[No Abstract] [Full Text] [Related]
4. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
Cooper HLF; Cloud DH; Young AM; Freeman PR
N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
[No Abstract] [Full Text] [Related]
5. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
6. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
Thakrar AP; Alexander GC; Saloner B
JAMA Netw Open; 2021 Dec; 4(12):e2138807. PubMed ID: 34905010
[TBL] [Abstract][Full Text] [Related]
7. Enhancing engagement between legislators and nursing to increase buprenorphine access.
Finnell DS; Schimmels J; Tierney M
Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154
[No Abstract] [Full Text] [Related]
8. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
Shover CL
Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
[No Abstract] [Full Text] [Related]
9. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
10. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
Breen CT; Fiellin DA
J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
[TBL] [Abstract][Full Text] [Related]
12. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
13. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
Vidyasagar N; Bunting SR; Arora VM; Ari M
JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
[TBL] [Abstract][Full Text] [Related]
14. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.
Knudsen HK; Lin LA; Lofwall MR
Subst Abus; 2020; 41(2):259-268. PubMed ID: 31295057
[No Abstract] [Full Text] [Related]
15. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
Lapeyre-Mestre M
Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
[No Abstract] [Full Text] [Related]
16. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
Chou R; Ballantyne J; Lembke A
Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
[No Abstract] [Full Text] [Related]
17. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
McBain RK; Dick A; Sorbero M; Stein BD
Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
[No Abstract] [Full Text] [Related]
18. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
19. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
[No Abstract] [Full Text] [Related]
20. Use of Buprenorphine to Treat Opioid Use Disorder.
Bartholow LAM; Pope J
J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
